182 related articles for article (PubMed ID: 33009502)
1. Deep phylogeny of cancer drivers and compensatory mutations.
Rochman ND; Wolf YI; Koonin EV
Commun Biol; 2020 Oct; 3(1):551. PubMed ID: 33009502
[TBL] [Abstract][Full Text] [Related]
2. The molecular evolution of cancer associated genes in mammals.
MacDonald N; Raven N; Diep W; Evans S; Pannipitiya S; Bramwell G; Vanbeek C; Thomas F; Russell T; Dujon AM; Telonis-Scott M; Ujvari B
Sci Rep; 2024 May; 14(1):11650. PubMed ID: 38773187
[TBL] [Abstract][Full Text] [Related]
3. Identifying Epistasis in Cancer Genomes: A Delicate Affair.
van de Haar J; Canisius S; Yu MK; Voest EE; Wessels LFA; Ideker T
Cell; 2019 May; 177(6):1375-1383. PubMed ID: 31150618
[TBL] [Abstract][Full Text] [Related]
4. Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W; Li Y; Wang Z
Sci Rep; 2018 May; 8(1):8256. PubMed ID: 29844492
[TBL] [Abstract][Full Text] [Related]
5. Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
Agajanian S; Odeyemi O; Bischoff N; Ratra S; Verkhivker GM
J Chem Inf Model; 2018 Oct; 58(10):2131-2150. PubMed ID: 30253099
[TBL] [Abstract][Full Text] [Related]
6. Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis.
Babenko VN; Basu MK; Kondrashov FA; Rogozin IB; Koonin EV
BMC Cancer; 2006 Feb; 6():36. PubMed ID: 16469093
[TBL] [Abstract][Full Text] [Related]
7. Identification and analysis of mutational hotspots in oncogenes and tumour suppressors.
Baeissa H; Benstead-Hume G; Richardson CJ; Pearl FMG
Oncotarget; 2017 Mar; 8(13):21290-21304. PubMed ID: 28423505
[TBL] [Abstract][Full Text] [Related]
8. Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers.
Reva B
BMC Genomics; 2013; 14 Suppl 3(Suppl 3):S8. PubMed ID: 23819556
[TBL] [Abstract][Full Text] [Related]
9. SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering.
Van den Eynden J; Fierro AC; Verbeke LP; Marchal K
BMC Bioinformatics; 2015 Apr; 16():125. PubMed ID: 25903787
[TBL] [Abstract][Full Text] [Related]
10. Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites.
Khan MM; Rydén AM; Chowdhury MS; Hasan MA; Kazi JU
Gene; 2011 Sep; 483(1-2):29-35. PubMed ID: 21640173
[TBL] [Abstract][Full Text] [Related]
11. Programmed genetic instability: a tumor-permissive mechanism for maintaining the evolvability of higher species through methylation-dependent mutation of DNA repair genes in the male germ line.
Zhao Y; Epstein RJ
Mol Biol Evol; 2008 Aug; 25(8):1737-49. PubMed ID: 18535014
[TBL] [Abstract][Full Text] [Related]
12. IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS.
Ma M; Wang C; Glicksberg BS; Schadt EE; Li SD; Chen R
Pac Symp Biocomput; 2017; 22():473-484. PubMed ID: 27896999
[TBL] [Abstract][Full Text] [Related]
13. Why Are Some Driver Mutations Rare?
Nussinov R; Tsai CJ; Jang H
Trends Pharmacol Sci; 2019 Dec; 40(12):919-929. PubMed ID: 31699406
[TBL] [Abstract][Full Text] [Related]
14. The Evolution of Human Cancer Gene Duplications across Mammals.
Tollis M; Schneider-Utaka AK; Maley CC
Mol Biol Evol; 2020 Oct; 37(10):2875-2886. PubMed ID: 32421773
[TBL] [Abstract][Full Text] [Related]
15. [Towards an inventory of oncogenic mutations in cancer].
Theillet C
Bull Cancer; 2010 Nov; 97(11):1223-9. PubMed ID: 21059490
[TBL] [Abstract][Full Text] [Related]
16. Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
Wang X; Zhang Y; Han ZG; He KY
Medicine (Baltimore); 2016 Feb; 95(8):e2697. PubMed ID: 26937901
[TBL] [Abstract][Full Text] [Related]
17. The rate of compensatory mutation in the DNA bacteriophage phiX174.
Poon A; Chao L
Genetics; 2005 Jul; 170(3):989-99. PubMed ID: 15911582
[TBL] [Abstract][Full Text] [Related]
18. SB Driver Analysis: a Sleeping Beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors.
Newberg JY; Black MA; Jenkins NA; Copeland NG; Mann KM; Mann MB
Nucleic Acids Res; 2018 Sep; 46(16):e94. PubMed ID: 29846651
[TBL] [Abstract][Full Text] [Related]
19. Cancer genes.
Vogt PK
West J Med; 1993 Mar; 158(3):273-8. PubMed ID: 8460509
[TBL] [Abstract][Full Text] [Related]
20. Identification of constrained cancer driver genes based on mutation timing.
Sakoparnig T; Fried P; Beerenwinkel N
PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
